BOC Sciences provides comprehensive custom branched peptide synthesis services backed by deep expertise in solid-phase peptide synthesis (SPPS), orthogonal protecting-group chemistry, chemoselective ligation, and advanced purification. We design, synthesize, purify, and characterize diverse branched peptide architectures — from symmetric MAP constructs and asymmetric multi-sequence peptides to peptide dendrimers and amphiphilic branched systems — supporting applications in antibody production, vaccine research, multivalent binding studies, antimicrobial development, and biomaterials design.
Branched peptide synthesis is the construction of peptide molecules in which two or more peptide chains radiate from a central core scaffold — most commonly a polyfunctional amino acid such as lysine, ornithine, or a synthetic tri-/tetra-functional template. Unlike linear peptides, branched architectures present multiple copies of one sequence (symmetric) or different functional sequences (asymmetric) on a single molecular framework. This multivalent topology enhances binding avidity, increases epitope density for immunogen design, and enables the integration of orthogonal functional domains — such as targeting, cell-penetrating, and antimicrobial motifs — into a single well-defined construct.
We prepare branched constructs bearing two or more identical peptide arms on a defined core for controlled multivalent presentation.
Asymmetric constructs combine different peptide sequences or functional domains within a single defined branched molecule.
BOC Sciences synthesizes MAP constructs that display repeated or different peptide epitopes on a branched lysine-based core.
We construct peptide dendrimers with defined cores, branching generations, internal sequences, and surface groups.
Branched peptide amphiphiles combine peptide arms with hydrophobic or lipid-like domains to tune assembly and interfacial behavior.
Our peptide bioconjugation capabilities enable labels, linkers, and functional payloads to be positioned on selected arms or termini.
BOC Sciences helps researchers translate a proposed branch architecture into a feasible synthesis, ligation, purification, and characterization plan.
BOC Sciences works with clients to define each specification dimension for branched peptide projects, ensuring that branch architecture, chemistry, purification level, and analytical deliverables are matched to the intended research application. Key specification dimensions include:
| Customization Parameter | Available Options & Service Support |
| Branching Architecture | Symmetric, asymmetric, two-arm, multi-arm, dendritic, cascade, and project-specific branched structures. |
| Branching Core | Lysine-based cores, polylysine matrices, diamino acid branch points, peptide cores, and custom multifunctional cores. |
| Number of Peptide Arms | Two-arm, four-arm, eight-arm, or customized multivalent configurations selected according to sequence and synthesis feasibility. |
| Peptide Arm Design | Identical or different sequences, variable arm lengths, homo- or heteromeric arrangements, and independently addressable functional arms. |
| Branching Orientation | N-terminal, C-terminal, side-chain-directed, convergent, divergent, or mixed-orientation branching. |
| Linkers and Spacers | Amino acid spacers, alkyl linkers, hydrophilic spacers, PEG units, cleavable linkers, and application-specific connecting groups. |
| Amino Acid Options | Natural, D-, noncanonical, isotopically labeled, selectively protected, and modification-ready amino acids. |
| Terminal and Side-Chain Modifications | Acetylation, amidation, lipidation, phosphorylation, biotinylation, PEGylation, labeling, and conjugation handles. |
| Scale and Purity | Feasibility batches, research-scale production, larger custom batches, crude material, purified fractions, and project-defined purity targets. |
| Analytical Support | HPLC, UPLC, LC-MS, MALDI-TOF MS, amino acid analysis, branch-completion assessment, and specialized testing when appropriate. |
Share the proposed sequence, branch diagram, arm number, core structure, modification sites, target scale, desired purity, and intended application. Our peptide scientists will evaluate route feasibility, protection requirements, branch construction, purification risks, and suitable analytical methods.
BOC Sciences reviews the client's peptide sequences, desired branch number, core chemistry, spacer needs, and application goals. We evaluate sequence hydrophobicity, predicted aggregation risk, protecting-group compatibility, and synthesis route feasibility before confirming a detailed synthesis plan.
Our team assembles the branched peptide by SPPS with orthogonal protecting-group strategies, sequential or convergent branch elongation, and chemoselective ligation when needed. Modifications — dyes, biotin, lipids, or PEG — are installed on-resin or post-cleavage at defined positions.
BOC Sciences purifies the branched peptide by preparative RP-HPLC, with SEC or ion-exchange polishing as needed, then performs orthogonal characterization by MALDI-TOF/ESI-MS, analytical HPLC, SEC-HPLC, and amino acid analysis to confirm identity, purity, and composition.
Clients receive the purified branched peptide together with a comprehensive data package — HPLC chromatograms, mass spectra, amino acid analysis, and aggregation data — plus application guidance for dissolution, storage, and downstream use in immunization, binding assays, or material studies.
As multiple peptide chains are elongated from a single core, steric crowding at the branch point can progressively reduce coupling efficiency, leading to deletion products, sequence truncation, and low overall yield. BOC Sciences addresses this by selecting branch-compatible core chemistries with adequate spacing, incorporating flexible spacer residues (Gly, Ahx, PEGn) between the core and each arm, optimizing coupling reagent and solvent combinations, and applying elevated-temperature or microwave-assisted protocols when sequence and resin compatibility allow. We monitor coupling completion at critical branch-elongation steps using Kaiser or chloranil tests and adjust conditions iteratively.
Branched peptides, particularly those with hydrophobic epitopes, lipid modifications, or high arm multiplicity, are prone to interchain aggregation during SPPS elongation, cleavage, or HPLC purification. This can reduce crude purity, complicate purification, and limit soluble product recovery. BOC Sciences mitigates aggregation risk through sequence-level hydrophobicity analysis, strategic spacer placement, pseudoproline dipeptide incorporation to disrupt on-resin aggregation, optimized cleavage cocktail composition, and SEC or ion-exchange polishing when RP-HPLC alone is insufficient. We also screen dissolution and storage buffer conditions to maintain product solubility.
In asymmetric branched peptide synthesis, incomplete deprotection at one branch site or unequal coupling rates between arms can generate mixed-arm products — constructs carrying unintended sequence combinations that are difficult to separate from the target. BOC Sciences controls branch fidelity by selecting orthogonal protecting-group pairs (Fmoc/Alloc, Fmoc/Dde, Fmoc/Mtt) with well-characterized deprotection selectivity, verifying deprotection completeness at each branch point, and using convergent fragment-ligation strategies when direct sequential elongation carries high risk. LC-MS and MALDI-TOF analysis at intermediate stages help detect and quantify mixed-arm species before purification.
Branched presentation can reduce epitope accessibility if peptide arms are too tightly packed, oriented unfavorably, or attached to the core without adequate spacing. This is particularly relevant for MAP constructs used in antibody production, where epitope recognition by B-cell receptors depends on proper arm orientation. BOC Sciences evaluates epitope length, charge distribution, and predicted secondary structure to recommend spacer type and length, compares N-terminal vs. C-terminal attachment orientations, and when requested, performs binding or antigenicity assessment to confirm that the branched format preserves target recognition before scale-up.
Collaborate with BOC Sciences to access custom branched peptide synthesis, orthogonal protecting-group strategies, chemoselective ligation, advanced purification, and comprehensive analytical data packages for your research and development programs.
Each sequence is evaluated according to branch number, arm composition, protecting-group compatibility, steric congestion, solubility, and modification requirements. This structure-specific review helps determine whether direct solid-phase growth, sequential arm synthesis, purified-fragment ligation, or a hybrid route offers the most practical balance of control and recoverability.
Our synthesis and analytical teams coordinate route development with crude-profile interpretation and fraction selection. Feedback from HPLC and mass spectrometry can therefore be used to distinguish incomplete backbone elongation, missing arms, residual fragments, side reactions, and purification losses, enabling targeted process adjustments instead of isolated troubleshooting.
BOC Sciences supports lysine and alternative diamino acid branch points, identical or different peptide arms, natural and noncanonical residues, varied terminal orientations, functional spacers, and diverse labels or conjugation handles. This flexibility allows the molecular design to be matched to the intended research question rather than a fixed catalog format.
Projects can begin with a feasibility batch to examine synthesis behavior, branch completion, crude complexity, and purification recovery. When additional material is needed, the selected route can be reassessed for resin loading, reagent use, reaction concentration, cleavage, isolation, and analytical controls appropriate to a larger research batch.
Client Needs: An immunology group needed a MAP-4 construct displaying four copies of a 14-residue extracellular loop epitope from a transmembrane receptor for rabbit polyclonal antibody production. The epitope contained two hydrophobic segments, and the group wanted to avoid KLH conjugation to reduce carrier-directed immune responses.
Challenges: The hydrophobic epitope segments caused on-resin aggregation during branch elongation, reducing crude purity. The client also needed confirmation that all four arms carried the full-length epitope — not truncated deletion products — before committing to an immunization campaign.
Solution: We evaluated three spacer designs (Gly-Gly, Ahx, and PEG4) between the lysine core and each arm across 12 microscale syntheses, monitoring coupling efficiency at the branch point and each epitope position. The PEG4-spacer variant showed the best crude purity profile. After preparative RP-HPLC purification, we confirmed full-length four-arm product identity by MALDI-TOF MS, assessed purity by analytical HPLC, and verified arm uniformity by peptide mapping with LC-MS/MS.
Outcome: The client received >20 mg of purified MAP-4 with confirmed four-arm integrity and an analytical data package supporting their immunization study design.
Client Needs: A chemical biology team required an asymmetric two-arm branched peptide: one arm carrying a cyclic RGD targeting motif and the other arm displaying a 10-residue pro-apoptotic peptide sequence, connected through a lysine core with an orthogonal fluorescent label at the C-terminus.
Challenges: The two arms required different protecting-group strategies to enable sequential elongation without cross-reactivity. The cyclic RGD arm needed on-resin cyclization, and the pro-apoptotic sequence contained a cysteine residue that required careful handling to avoid disulfide scrambling.
Solution: We designed an Fmoc/Alloc orthogonal protection scheme — the RGD arm was assembled first via Fmoc-SPPS with on-resin cyclization, followed by Alloc deprotection and elongation of the pro-apoptotic arm. Sixteen reaction conditions were screened for cyclization efficiency and branch deprotection selectivity. The construct was purified by RP-HPLC, and identity was confirmed by MALDI-TOF MS and LC-MS/MS branch mapping. The C-terminal fluorescent label was installed via thiol-maleimide conjugation after cleavage.
Outcome: The client obtained a purified asymmetric branched peptide with confirmed dual-arm composition and site-specific fluorescent labeling for targeted cell-uptake studies.
Client Needs: A biomaterials research group needed a G2 lysine-based peptide dendrimer with eight terminal antimicrobial peptide (AMP) sequences and a C-terminal cysteine focal point for thiol-reactive surface immobilization on gold-coated sensor chips.
Challenges: The AMP sequences were cationic and amphipathic, creating strong charge repulsion between arms during G1-to-G2 branching. Early attempts produced significant deletion products — dendrimers carrying only five to seven AMP arms instead of eight — and the free cysteine at the focal point required post-cleavage handling under reducing conditions.
Solution: We screened four coupling protocols at the G1-to-G2 branching step, adjusting reagent stoichiometry, coupling time, and solvent composition across 20 test reactions. Double-coupling with HATU/DIPEA in DMF/DMSO (4:1) gave the best eight-arm product distribution. RP-HPLC purification isolated the full eight-arm species, confirmed by MALDI-TOF MS. The cysteine focal point was maintained under reducing conditions throughout workup, and free thiol content was verified by Ellman's assay before delivery.
Outcome: The client received a purified G2 dendrimer with confirmed eight-arm loading and an active focal-point thiol for surface-immobilization studies.
BOC Sciences supports symmetric and asymmetric multi-arm peptides, multiple antigen peptides (MAPs), peptide dendrimers, branched peptide amphiphiles, and modified or conjugated branched constructs. The number of arms, branching core, sequence arrangement, terminal orientation, spacers, and functional groups can be adjusted according to the research objective. For structures containing hydrophobic sequences, unequal arms, noncanonical residues, or multiple modifications, our scientists assess steric congestion, protecting-group compatibility, aggregation risk, and purification feasibility before recommending a suitable direct, sequential, convergent, or hybrid synthesis route.
Please provide a complete structural diagram or clear connection map showing each peptide-arm sequence, N- and C-terminal orientation, branching core, branch residues, and attachment positions. The requested terminal groups, side-chain modifications, labels, linkers, target scale, desired purity, and downstream research application should also be included. Reference structures, analytical requirements, solubility information, or results from previous synthesis attempts can further support the assessment. These details allow our scientists to evaluate assembly order, orthogonal protection requirements, ligation strategy, purification difficulty, and appropriate characterization methods before confirming the project plan.
Identical arms in a symmetric construct may be extended simultaneously after the branching groups are exposed. Asymmetric structures generally require orthogonal protecting groups that allow individual amino sites to be deprotected and coupled in a controlled order. For more complex designs, separate peptide arms can be synthesized and purified before convergent attachment through amide coupling, thiol chemistry, oxime ligation, hydrazone formation, or click-enabled reactions. Small-scale cleavage checks, HPLC, and mass spectrometry can be used during development to monitor arm completion and reduce missing-arm products, incorrect connections, or byproducts caused by premature deprotection.
Crude branched peptides are initially profiled by analytical HPLC to determine the complexity of the product mixture. Preparative reversed-phase HPLC, ion-exchange separation, size-based separation, or other methods may then be selected according to hydrophobicity, charge, molecular size, and impurity behavior. Purified fractions are commonly evaluated by analytical HPLC or UPLC, while LC-MS or MALDI-TOF MS supports molecular-mass confirmation. Amino acid analysis and other structure-dependent techniques may also be used to assess branch completion, confirm arm composition, and distinguish the target product from deletion sequences, residual fragments, or incompletely branched variants.
Yes. Branched peptides can incorporate acetylation, amidation, phosphorylation, lipidation, PEG spacers, D-amino acids, noncanonical residues, stable isotopes, fluorescent labels, biotin, chelators, and other research-use functionalities. Click-compatible groups, thiols, or additional conjugation handles may be positioned on a selected arm, branching core, terminus, or side chain. Route design considers the stability of each modification, compatibility with protecting-group and cleavage conditions, positional accessibility, solubility, and effects on purification. Depending on the structure, the functionality may be introduced during solid-phase assembly or through selective post-synthetic conjugation.
BOC Sciences offered an extensive range of orthogonally protected amino acid building blocks and core scaffolds for our branched peptide project. Their team helped us compare different branch-point chemistries and quickly identify a synthesis route that matched our sequence complexity and application needs.
— Dr. Schneider, Principal Investigator, Immunology Research
The BOC Sciences team handled a challenging asymmetric two-arm peptide synthesis requiring Fmoc/Alloc orthogonal deprotection and on-resin cyclization of one branch. Their protecting-group strategy was well-planned, and the analytical data confirmed clean branch differentiation with no detectable cross-reactivity between arms.
— Chapman, Senior Scientist, Chemical Biology
Our G2 peptide dendrimer project generated a complex crude mixture with multiple deletion species. BOC Sciences optimized the preparative HPLC gradient and collected targeted fractions that enriched the full eight-arm product. The final material showed clean MALDI-TOF confirmation and good solubility in our assay buffer.
— Dr. Murphy, Research Director, Biomaterials Development
The analytical data package was thorough and well-organized — HPLC chromatograms, MALDI-TOF spectra, amino acid analysis, and SEC aggregation data were all clearly annotated. This level of characterization detail gave our team confidence in the branched peptide identity and purity before starting our immunization study.
— Rhodes, Lead Scientist, Vaccine Research
If you have any questions or encounter issues on this page, please don't hesitate to reach out. Our support team is ready to assist you.
